|
Originally published In Press as doi:10.1074/jbc.M003504200 on August 1, 2000
J. Biol. Chem., Vol. 275, Issue 42, 32775-32782, October 20, 2000
Molecular Identification of Cytosolic Prostaglandin
E2 Synthase That Is Functionally Coupled with
Cyclooxygenase-1 in Immediate Prostaglandin E2
Biosynthesis*
Toshihiro
Tanioka,
Yoshihito
Nakatani,
Natsuki
Semmyo,
Makoto
Murakami, and
Ichiro
Kudo
From the Department of Health Chemistry, School of Pharmaceutical
Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku,
Tokyo 142, Japan
Received for publication, April 24, 2000, and in revised form, July 31, 2000
 |
ABSTRACT |
Here we report the molecular identification of
cytosolic glutathione (GSH)-dependent prostaglandin (PG)
E2 synthase (cPGES), a terminal enzyme of the
cyclooxygenase (COX)-1-mediated PGE2 biosynthetic pathway.
GSH-dependent PGES activity in the cytosol of rat brains,
but not of other tissues, increased 3-fold after lipopolysaccharide
(LPS) challenge. Peptide microsequencing of purified enzyme revealed
that it was identical to p23, which is reportedly the weakly bound
component of the steroid hormone receptor/hsp90 complex. Recombinant
p23 expressed in Escherichia coli and 293 cells exhibited
all the features of PGES activity detected in rat brain cytosol. A
tyrosine residue near the N terminus (Tyr9), which is known
to be critical for the activity of cytosolic GSH
S-transferases, was essential for PGES activity. The
expression of cPGES/p23 was constitutive and was unaltered by
proinflammatory stimuli in various cells and tissues, except that it
was increased significantly in rat brain after LPS treatment. cPGES/p23
was functionally linked with COX-1 in marked preference to COX-2 to produce PGE2 from exogenous and endogenous arachidonic
acid, the latter being supplied by cytosolic phospholipase
A2 in the immediate response. Thus, functional coupling
between COX-1 and cPGES/p23 may contribute to production of the
PGE2 that plays a role in maintenance of tissue homeostasis.
 |
INTRODUCTION |
Biosynthesis of prostaglandin
(PG)1 E2, the
most common prostanoid with potent bioactivities, is regulated by three
sequential steps of the cyclooxygenase (COX) pathway. Phospholipase
A2 (PLA2) initiates this pathway by releasing
arachidonic acid (AA) from membrane glycerophospholipids. Of more than
10 members of the PLA2 family characterized to date,
cytosolic PLA2 (cPLA2) and several secretory
PLA2s are involved in supplying AA to either of the two COX
isozymes, COX-1 and COX-2, depending upon the phases of cell activation
(1-3). The constitutive COX-1 is mainly utilized in immediate
PGE2 biosynthesis, which occurs within several minutes after stimulation with Ca2+ mobilizers, whereas the
inducible COX-2 mediates the delayed PGE2 biosynthesis,
which lasts for several hours following proinflammatory stimuli.
Although COX-1 and COX-2 have been reported to exhibit subtle
differences in AA requirements in that COX-2 is favored over COX-1 at
low AA concentrations (3-5) and subcellular localizations (6), their
functional segregation in the PGE2 biosynthetic response
cannot be fully explained only by these aspects.
The activity of PGES, which catalyzes conversion of COX-derived
PGH2 to PGE2, has been detected in both
cytosolic and microsomal fractions of various cells, and in most, if
not all, cases it requires glutathione (GSH) for optimal activity
(7-9). Although several groups have attempted to purify this critical
enzyme to near homogeneity for the last 20 years (7-9), such trials
have been unsuccessful. The PGES enzyme purified from human brain
cytosol was identified as a GSH S-transferase (GST), which
converts PGH2 to PGE2, PGD2, and
PGF2 nonspecifically (9). GSH-independent PGES with a
molecular mass of 31 kDa was recently purified from bovine heart (10).
Interestingly, PGES activity has been shown to be strongly induced by
proinflammatory stimuli in macrophages (11, 12). More recently,
microsomal GST1-like 1 (MGST1-L1), a member of the MAPEG
(membrane-associated proteins
involved in eicosanoid and glutathione
metabolism) superfamily, has been shown to exhibit significant PGES
activity (13, 14).
In this study, we report the molecular identification of cytosolic PGES
(cPGES), a GSH-requiring enzyme that is expressed ubiquitously in a
wide variety of cells and tissues. Importantly, this enzyme is capable
of converting COX-1-, but not COX-2-, derived PGH2 to
PGE2 efficiently. Our present results, together with
identification of the inducible membrane-associated PGES that is
preferentially coupled with COX-2 as described in the accompanying
paper (15), revealed that segregated utilization of the biosynthetic
enzymes in different phases of PG production also occurs at the step of terminal synthases.
 |
EXPERIMENTAL PROCEDURES |
Animals--
Wistar rats (7 weeks old, male) were purchased from
Japan Bio-Supply center (Tokyo, Japan). Rabbits (New Zealand White,
1-kg body weight, female) were from Saitama Experimental Animal Supply (Saitama, Japan).
Cells--
Human embryonic kidney 293 cells were obtained from
Japanese Cancer Resources Bank. Rat fibroblastic 3Y1 cells were donated by Dr. Y. Uehara (National Institute of Infectious Disease, Tokyo, Japan). Human cervix epithelial HeLa cells, human stomach MKN45 cells,
human glial U251 cells, human fibroblastic WI38 cells, human
neuroblastoma GOTO cells, Chinese hamster ovary (CHO) cells, mouse
osteoblastic MC3T3-E1 cells, and mouse fibroblastic L929 cells were
obtained from the RIKEN Cell Bank. GOTO, HEK293, CHO, MKN45 and L929
were cultured in RPMI 1640 medium (Nissui Pharmaceutical) containing
10% fetal calf serum (FCS; Bioserum), WI38. U251 and 3Y1 in DMEM
(Nissui Pharmaceutical) containing 10% FCS, and MC3T3-E1 in
-minimal essential medium (Dainippon Pharmaceutical) containing 10%
FCS.
Materials--
The goat anti-human COX-2 and rabbit anti-human
cPLA2 antibodies were purchased from Santa Cruz. The rabbit
anti-mouse COX-1 antibody was provided by Dr. W. L. Smith
(Michigan State University, East Lansing, MI). cDNA probes
for human COX-1, human COX-2 and mouse COX-2 were described previously
(2, 16). LipofectAMINE Plus, LipofectAMINE 2000, Opti-MEM, and TRIzol
reagent were obtained from Life Technologies. Bacterial LPS
(Salmonella minnesota Re 595),
1-chloro-2,4-dinitrobenzene (CDNB), indomethacin, and GSH were
purchased from Sigma. Ethacrynic acid, 1,2-dichloro-4-nitrobenzene, and
p-nitrophenethyl bromide were from Wako. Freund's complete and incomplete adjuvants were from Difco Laboratories. AA,
PGH2, rabbit anti-human COX-1 antibody, and the enzyme
immunoassay kits for PGE2 were from Cayman Chemical.
Oligonucleotide primers were from Amersham Pharmacia Biotech.
Geneticin, hygromycin, and the mammalian expression vectors pCR3.1 and
pCDNA3.1/hyg(+) were purchased from Invitrogen. A23187 was
purchased from Calbiochem. Human and mouse interleukin (IL)-1 and
tumor necrosis factor (TNF) were from Genzyme. Fluorescein
isothiocyanate-conjugated goat anti-rabbit IgG and horseradish
peroxidase-conjugated anti-rabbit and mouse IgGs were purchased from
Zymed Laboratories Inc. Other reagents were obtained
from Wako Pure Chemical Industries. Computational analysis on the
protein and cDNA sequences were performed using the GENETYX program
(Software Development).
Assay of Enzymatic Activity of PGES--
PGES activities in cell
lysates were measured by assessment of conversion of PGH2
to PGE2 as previously reported (11). The cells were scraped
off from the dishes and disrupted by sonication using Branson Sonifier
(10 s, three times, 1-min interval) in 400 µl of 10 mM
Tris-HCl (pH 8.0). After centrifugation of the sonicates at 1,700 × g for 10 min at 4 °C, the supernatants were used as
the enzyme source. An aliquot of each lysate (10 µg of protein
equivalents) was incubated with 0.5 µg of PGH2 for
30 s at 24 °C in 0.1 ml of 0.1 M Tris-HCl (pH 8.0),
containing 1 mM GSH and 5 µg of indomethacin. After
terminating the reaction by the addition of 100 mM
FeCl2, PGE2 contents in the supernatants were
quantified by use of the enzyme immunoassay kit. Protein concentrations
were determined by the protein assay kit (Pierce) using bovine serum
albumin (BSA) as a standard.
Purification of PGES from Rat Brain Cytosol--
Brains obtained
from 10 Wistar rats 48 h after intravenous injection of 150 µg/kg LPS were homogenized in 100 ml of SET buffer comprising 20 mM Tris-HCl (pH 7.4), 250 mM sucrose, 5 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride
by using a Potter homogenizer. After centrifugation at 100,000 × g, the supernatant was subjected to 60-80% ammonium
sulfate precipitation. The precipitate obtained by centrifugation for
30 min at 10,000 × g at 4 °C was dissolved in SET
buffer, dialyzed against 20 mM Tris-HCl (pH 7.4) containing 150 mM NaCl, 1 mM EDTA, 0.1 mM
phenylmethylsulfonyl fluoride, 1 µM leupeptin, and 1 µM antipain, and then applied to a DEAE-Sephacel ion-exchange column (1 × 7 cm) (Amersham Pharmacia Biotech) at a
flow rate of 30 ml/h. The bound proteins were eluted with 25 mM Tris-HCl (pH 7.4) containing 1 mM EDTA and a
linear gradient of 0.15-1 M NaCl. Fractions containing
PGES activity were concentrated to 1 ml using Centriprep 10 (Amicon)
and applied to a Superdex 200 gel filtration column (Amersham Pharmacia
Biotech) equilibrated with 20 mM Tris-HCl (pH 7.4)
containing 150 mM NaCl, 1 mM EDTA, and 0.1 mM phenylmethylsulfonyl fluoride at a flow rate of 0.5 ml/min. A 10-µl aliquot of each fraction was taken for PGES enzyme assay.
Peptide Microsequencing--
The protein band on the first
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
was visualized by Coomassie Brilliant Blue, cut out from the gel, and
then digested in the second gel with 10 µg of V8 protease (Sigma).
The resultant peptides were electrotransferred to a polyvinylidene
difluoride membrane (Millipore), and the three major peptide fragments
obtained were subjected to amino acid sequencing using an Applied
Biosystems 473A protein sequencer, as described previously (17).
Isolation of cPGES/p23 cDNA--
Total RNA from HeLa cells
was subjected to a reverse transcription reaction using RNA PCR kit
(avian myeloblastosis virus) (Takara Biomedicals). cDNA thus
obtained was subjected to PCR using the human p23 (18) primers
5'-ATGCAGCCTGCTTCTGCA-3' and 5'-TTACTCCAGATCTGGCAT-3' (94 °C
for 30 s, 50 °C for 30 s, and 72 °C for 30 s, for
25 cycles). An amplified product of the expected size was subcloned
into pCR3.1 (Invitrogen) and transfected into E. coli
Top10F' (Invitrogen). The plasmid was isolated and sequenced using a
thermo sequenase fluorescent-labelled primer cycle sequencing kit with
7-deaza-dGTP (Amersham Pharmacia Biotech) and an autofluorometric DNA
sequencer DSQ-1000L (Shimadzu).
Preparation of Recombinant cPGES/p23--
Human p23 cDNA
(18) was subcloned into pET21c (Novagen) and transformed into E. coli BL21 (DE3) (Stratagene). The cells were cultured until they
reached the late lag phase, and 0.3 mM isopropyl-1-thio- -D-galactopyranoside was added to
induce (His)6-tagged protein. Bacterial cell pellets were
lysed in 20 mM Tris-HCl (pH 8) containing 0.5 M
NaCl, 10% glycerol, and 6 M guanidine HCl by stirring for
30 min at room temperature. After centrifugation at 15,000 × g for 30 min at 4 °C, the resulting supernatants were applied to a nickel-nitrilotriacetic acid-agarose column (Qiagen) preequilibrated with 100 mM NiSO4 at a flow
rate of 10 ml/h. After washing, the bound protein was eluted with the
same buffer containing 20-60 mM imidazole in a stepwise manner.
Site-directed Mutagenesis--
To obtain cPGES/p23 Y9N mutant,
mismatched primer PCR was carried out using ex Taq
polymerase with cPGES/p23 cDNA as a template and the primers 5'-ATG
CAG CCT GCT TCT GCA AAG TGG AAC G-3' (the mutated base is
underlined) and 5'-TTA CTC CAG ATC TGG CAT-3'. PCR conditions were
94 °C for 30 s, 50 °C for 30 s, and 72 °C for
30 s, for 25 cycles. The fragment obtained was subcloned into pCR3.1 and sequenced.
Expression of cPGES/p23 in 293 Cells--
The cDNA flanking
the entire open reading frame of human cPGES/p23 was subcloned into the
mammalian expression vector pCDNA3.1/hyg(+) and transfected into
293 cells stably expressing human COX-1 or COX-2, which we had
previously established (2), using LipofectAMINE Plus according to the
manufacturer's instruction. Briefly, 1 µg of each plasmid was mixed
with 4 µl of LipofectAMINE and 6 µl of Plus reagent in 200 µl of
Opti-MEM, left for 15 min, and then added to cells that had attained
70% confluence in six-well plates (Iwaki Glass) in 1 ml of Opti-MEM.
After incubation for 4 h, 2 ml of fresh culture medium was added.
After 18 h, the medium was replaced with 2 ml of fresh medium, and
the culture was continued for 3 days. In order to establish stable
transfectants, cells transfected with each cDNA were cloned by
limiting dilution in 96-well plates (Iwaki Glass) in culture medium
supplemented with 50 µg/ml hygromycin. After 3-4 weeks of culture,
single colonies were picked up and expanded. Expression of cPGES/p23
and each COX was assessed by RNA blotting and immunoblotting, as
described below.
Cell Activation--
All procedures were described in our
previous reports (1-3). Briefly, 293 cells (5 × 104/ml) were seeded into each well of 24- or 48-well plates
in 1 and 0.5 ml of culture medium, respectively. After culture for 4 days, the cells were washed once with culture medium and then incubated
with 250 µl (24-well plate) or 100 µl (48-well plate) of various
concentrations of AA or 10 µM A23187 in medium containing 1% FCS for 30 min or 1 ng/ml IL-1 in medium containing 10% FCS for
4 h. The supernatants were subjected to the PGE2
enzyme immunoassay. Activation of other cell lines was carried out in a
similar way.
Preparation of Antibody against cPGES/p23--
The
(His)6-tagged cPGES/p23 (500 µg) in 500 µl of
phosphate-buffered saline was mixed with an equal volume of Freund's
complete adjuvant and injected into rabbits. Immunization was repeated every 3 weeks with the same amounts of the antigen mixed with an equal
volume of Freund's incomplete adjuvant. Serum titers were checked by
the enzyme-linked immunosorbent assay (see below), followed by Western
blotting (see below) using the purified recombinant (His)6-tagged cPGES/p23 and the lysate of HeLa cells.
In the enzyme-linked immunosorbent assay, 1 µg/ml recombinant
(His)6-tagged cPGES/p23 was coated on Immulon 2 plates
(Dynatech Laboratories) (50 µl/well) overnight at 4 °C. Subsequent
procedures were performed at room temperature. After washing with 10 mM Tris-HCl (pH 7.4) containing 0.05% Tween 20 and 150 mM NaCl (TBS-T), the plates were incubated for 1 h
with 5% skim milk in PBS. After six washes with TBS-T, serial
dilutions of rabbit antisera were added to the plates (50 µl/well)
and incubated for 1 h. After 6 washes with TBS-T, the plates were
incubated with horseradish peroxidase-conjugated anti-rabbit IgG (50 µl/well) at a 1:1,000 dilution for 1 h. After 6 washes, the
plates were incubated with o-phenylenediamine. After
terminating the reaction by adding 4 N
H2SO4, absorbance at 490 nm was measured.
RNA Blotting--
Approximately equal amounts (~10 µg) of
the total RNAs obtained from the transfected cells were applied to
separate lanes of 1.2% (w/v) formaldehyde-agarose gels,
electrophoresed, and transferred to Immobilon-N membranes (Millipore).
The resulting blots were then probed with the respective cDNA
probes that had been labeled with [32P]dCTP (Amersham
Pharmacia Biotech) by random priming (Takara Biomedicals). All
hybridizations were carried out as described previously (19).
SDS-PAGE/Immunoblotting--
Cell lysates (105 cell
equivalents) or culture supernatants were subjected to SDS-PAGE using
15% (w/v) gels for cPGES/p23 and 10% gels for COXs under reducing
conditions. The separated proteins were electroblotted onto
nitrocellulose membranes (Schleicher & Schuell) using a semidry blotter
(MilliBlot-SDE system; Millipore). The membranes were probed with the
respective antibodies and visualized using the ECL Western blot system
(PerkinElmer Life Sciences), as described previously (19).
Immunofluorescent Confocal Microscopic Analysis--
Cells were
seeded onto cover glasses (Matsunami Glass) at 1 × 105 cells/ml and cultured for 1 day. After removing the
supernatants, the cells were fixed with 10% (v/v) formalin in PBS for
30 min at 4 °C. The cells were then treated 0.2% (v/v) Triton X-100
for 2 min, washed six times, and incubated for 1 h with 3% (w/v)
BSA in PBS (PBS-BSA). After three washes, the cells were incubated with
rabbit anti-cPGES/p23 antibody (1:200 dilution) in PBS-BSA for 2 h, washed three times, and then incubated with fluorescein isothiocyanate-conjugated anti-rabbit IgG (1:100 dilution) in PBS-BSA
for 1 h. After six washes, the coverslips were mounted on glass
slides using Perma Fluor (Japan Tanner) and examined using a Fluoview
laser fluorescence microscope (Olympus).
Transfection of Antisense cPGES/p23 cDNA into 3Y1
Cells--
Approximately 4 µg of cPGES/p23 cDNA subcloned into
pCR3.1 in an inverse direction were incubated with 5 µl of
LipofectAMINE 2000 reagent in 200 µl of Opti-MEM for 15 min at room
temperature and then added to cells that had attained 60-80%
confluence in six-well plates and been supplemented with 800 µl of
Opti-MEM. After incubation for 6 h at 37 °C, 1 ml of DMEM
supplemented with 2% FCS was added, and the culture was continued for
another day. Then the cells were trypsinized, seeded into 24-well
plates, and cultured for 2 days. After washing once with DMEM, the
cells were stimulated for 30 min with 10 µM A23187 in
DMEM or for 12 h with 1 ng/ml mouse IL-1 and mouse TNF in
DMEM containing 2% FCS. The supernatants were taken for
PGE2 enzyme immunoassay, and the cells were subjected to
PGES enzyme assay and immunoblotting.
 |
RESULTS |
Detection of PGES Activity in the Cytosol of Rat Tissues--
In
an effort to identify PGES isoforms, we measured PGES activity, which
converts PGH2 to PGE2, in the cytosol of
various rat tissues before and 48 h after injection of LPS. All
tissues examined contained significant PGES activity that was not
affected by LPS, except that the activity in brain increased up to
3-fold 48 h after LPS challenge (Fig.
1A). This activity was
stimulated markedly by GSH and was inhibited by CDNB, a substrate for
several GST enzymes (20) (Fig. 1B).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 1.
Detection of PGES activity in rat
tissues. A, cytosolic PGES activity in the cytosol
fraction of various rat tissues with or without treatment with LPS for
48 h was measured in the presence of 1 mM GSH.
B, PGES activity in the cytosol fraction of LPS-treated rats
was assessed in the presence or absence of 1 mM GSH and 1 mM CDNB.
|
|
Purification of PGES--
LPS-sensitive PGES activity in rat brain
cytosol fraction was recovered in the 60-80% ammonium sulfate
precipitated fraction (Fig.
2A). When this fraction was
dialyzed and then applied to DEAE-Sephacel ion-exchange column
chromatography, a single major peak of PGES activity was eluted with
0.5 M NaCl (Fig. 2B). The activity obtained from
LPS-treated rat brains was significantly higher than that obtained from
untreated animals. When the fractions containing PGES activity were
then applied to Superdex 200 gel filtration, there were three major
peaks that exhibited significant PGES activity, among which only the
activity eluted in fractions corresponding to a molecular mass of ~50
kDa (around fraction 78) showed severalfold higher activity than that
in replicate fractions purified from rats not treated with LPS (Fig.
2C). On SDS-PAGE, this activity comigrated with a major
protein with an apparent molecular mass of 26 kDa, which was detected
more faintly in the untreated group. The specific activity of the peak
fraction purified from LPS-treated rat brains after gel filtration was estimated to be approximately 5 µmol/min/mg of protein. This activity showed dependence on GSH and was inhibited by CDNB (data not shown). There was no detectable GST activity toward several cytosolic GST
substrates, such as CDNB, 1,2-dichloro-4-nitrobenzene,
p-nitrophenethyl bromide, and ethacrynic acid (data not
shown). On the other hand, the other two higher molecular weight PGES
peaks, which were eluted in fractions 53 and 69 in both LPS-treated and
-untreated groups (Fig. 2C), were fairly insensitive to CDNB
(data not shown). These results suggest that there are several proteins
that exhibit PGES activity with different enzymatic properties in the
cytosol.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 2.
Purification of PGES from rat brain
cytosol fractions. A, ammonium sulfate precipitation.
PGES activity in 0-60% and 60-80% ammonium sulfate-precipitated
fractions obtained from rat brains with or without treatment with LPS
for 48 h was measured in the presence of 1 mM GSH.
B, fractions precipitated by 60-80% ammonium sulfate were
dialyzed and subjected to DEAE-Sephacel ion-exchange column
chromatography. Bound proteins were eluted with a linear gradient of
NaCl from 0.15 to 1 M. A 10-µl portion of each fraction
was taken for PGES assay. C, fractions containing PGES
activity in panel B were applied to Superdex 200 gel filtration, and a 10-µl portion of each fraction was taken for
PGES assay. Fractions 71-83 were subjected to SDS-PAGE, and proteins
were visualized by silver staining. Detailed chromatographic procedures
are described under "Experimental Procedures."
|
|
Molecular Indentification of Cytosolic PGES--
Peptide mapping
of the 26-kDa protein revealed that the partial amino acid sequences
(MDPASAKWYDRRDYVFIEFC, KSKLCFSCLG, and IDLFHCIDPN) were identical to
those of the corresponding portions (1-20, 33-42, and 53-62,
respectively) of human p23, a cytosolic protein that is the weakly
bound component of the steroid hormone receptor/hsp90 complex with a
putative chaperone function (18, 21). We therefore isolated the
full-length human p23 cDNA from HeLa cells and expressed it in
E. coli as a C-terminally (His)6-tagged protein.
The recombinant protein purified by nickel-chelating column had
significant PGES activity in the presence of GSH and was inhibited by
CDNB (Fig. 3A), whereas
formation of other PGs was negligible (data not shown). The
Km and Vmax values of the
recombinant protein for PGH2 were estimated to be 14 µM and 190 nmol/min/mg of protein, respectively, in our
in vitro assay system. GST activity was undetected when
CDNB, 1,2-dichloro-4-nitrobenzene, p-nitrophenethyl bromide,
and ethacrynic acid were used as substrates (data not shown).
Furthermore, PGES activity in lysate of p23-transfected HEK293 cells
was stimulated markedly by GSH as compared with mock-transfected cells,
and was inhibited by CDNB (Fig. 3B). Thus, we conclude that
p23 indeed possesses PGES activity, and therefore designate it
cPGES/p23 (c stands for cytosolic) hereafter.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 3.
Biochemical analyses of cPGES/p23.
A, the PGES activity of the bacteria-derived recombinant p23
protein was measured in the presence or absence of 1 mM GSH
and 1 mM CDNB. B, the PGES activity in lysates
of HEK293 cells 3 days after transfection of human cPGES/p23
cDNA/pCR3.1 or the control vector was measured in the presence or
absence of 1 mM GSH and 1 mM CDNB.
|
|
Although the homology between cPGES/p23 and other known cytosolic GSTs
(including hematopoietic PGD2 synthase (Ref. 22)) is low
(~20%), near the N terminus cPGES/p23 has a tyrosine residue (Tyr9) that is conserved in several other cytosolic GSTs as
well as hematopoietic PGD2 synthase (Fig.
4A). The tyrosine residue in this position serves as a GSH acceptor, thereby being essential for
catalytic activity (20, 22). As shown in Fig. 4B, the cPGES/p23 mutant in which Tyr9 was replaced by Asn
exhibited virtually no PGES activity when transfected into HEK293
cells.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 4.
Tyr9 is essential for cPGES/p23
activity. A, alignment of the N-terminal amino acid
sequences of several human cytosolic GSTs, hematopoietic
PGD2 synthase (hPGDS), and cPGES/p23. A tyrosine
residue essential for the catalytic activity is boxed.
B, cPGES/p23 (wild-type (WT) and Y9N mutant)
cDNA subcloned into pCR3.1 and the empty vector were transfected
into HEK293 cells, and PGES activity in cell lysates 3 days after
transfection was measured in the presence of 1 mM GSH.
Expression of recombinant protein was confirmed by immunoblotting using
anti-cPGES/p23 antibody (top panel).
|
|
Expression of cPGES/p23 in Various Cells and Tissues--
RNA blot
analysis showed that cPGES/p23 was most abundantly expressed in the
testis, and was also expressed in various tissues of the rat (Fig.
5A). In most tissues,
expression was unchanged following LPS treatment. Exceptionally,
cPGES/p23 mRNA expression in brain was increased approximately
3-fold after treatment with LPS (Fig. 5A), a result
consistent with increased PGES activity in brain cytosol fraction (Fig.
1A). Immunoblotting using anti-cPGES/p23 antibody confirmed
the increased expression of cPGES/p23 protein in LPS-treated rat brain
cytosol fraction (Fig. 5B). cPGES/p23 mRNA was detected
in the kidney only faintly (Fig. 5A), whereas PGES activity
in the kidney cytosol was higher than that in other tissues (Fig.
1A), suggesting that there are other types of PGES in this
tissue. cPGES/p23 was expressed constitutively and was not altered
significantly by stimulation with cytokines (TNF and IL-1 ) in all
cell lines examined (Fig. 5C). Confocal microscopic analysis
using an anti-cPGES antibody revealed that cPGES is located in the
cytosol of these cells (Fig. 6).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
Tissue and cellular distribution of
cPGES/p23. A, expression of cPGES/p23 mRNA in
various rat tissues. Total RNA (10 µg) obtained from various tissues
of rat before and 48 h after injection of LPS was subjected to RNA
blotting using cPGES/p23 cDNA as a probe. B, increased
expression of cPGES/p23 protein in LPS-treated rat brain. The
100,000 × g supernatants and pellets of rat brain
homogenates were subjected to immunoblotting using the anti-cPGES/p23
antibody. C, expression of cPGES/p23 mRNA in various
cell lines before and 24 h after stimulation with 1 ng/ml IL-1
and 100 units/ml TNF .
|
|

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 6.
Subcellular distribution of cPGES/p23.
Cells were fixed with folmalin, permeabilized, and then incubated
sequentially with rabbit anti-cPGES/p23 antibody and fluorescein
isothiocyanate-conjugated anti-rabbit IgG. The cells were
mounted, and their fluorescence was visualized using a laser scanning
confocal microscope.
|
|
Functional Coupling between cPGES/p23 and COXs--
To assess
whether cPGES/p23 plays a role in PGE2 production by live
cells, human cPGES/p23 cDNA was cotransfected with either COX-1 or
COX-2 into HEK293 cells to establish their stable transfectants (Fig.
7A). Whereas cells expressing
COX-1 alone produced significantly more PGE2 than control
cells, particularly when a high concentration (10 µM) of
AA was added, as reported previously (2), cotransfection of COX-1 and
cPGES/p23 led to a marked increase in PGE2 that was detectable at lower AA concentrations (Fig. 7B,
left). Approximately 10-fold increase in PGE2
formation by COX-1-cPGES/p23 cotransfectants relative to that by COX-1
single transfectants at all AA doses tested (Fig. 7B,
left) appeared to correlate with the expression levels of
overexpressed versus endogenous cPGES/p23 (Fig.
7A). On the other hand, PGE2 generation by
COX-2-expressing cells was increased minimally even after cPGES
cotransfection (Fig. 7B, right).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 7.
Functional coupling between COXs and
cPGES/p23 in HEK293 transfectants. A, the expression
levels of COX-1, COX-2, and cPGES/p23 in HEK293 cells stably
transfected with their cDNAs, alone or in combination, were
assessed by RNA blotting and immunoblotting. B, conversion
of exogenous AA to PGE2. Cells transfected with both cPGES
and either COX (filled circles), cells transfected with
either COX alone (open circles), and control cells
(open squares) were incubated for 30 min with the indicated
concentrations of AA, and PGE2 released into the
supernatants was quantified. C, production of
PGE2 from endogenous AA. HEK293 cells stably transfected
with cPLA2, COX-1, COX-2, and cPGES/p23, alone or in
combination, were stimulated for 30 min with 10 µM A23187
(left) or for 4 h with 1 ng/ml human IL-1
(right). Expression of cPLA2 as assessed by RNA
blotting is shown in the inset of the right
panel.
|
|
To assess the metabolism of endogenous AA, these transfectants were
stimulated for 30 min with A23187 (immediate response) or for 4 h
with IL-1 (delayed response). Although A23187-induced PGE2
generation was not increased significantly in cells coexpressing COX-1
and cPGES/p23, further introduction of cPLA2, which caused the burst release of AA (1), led to a dramatic increase in the
production of PGE2 (Fig. 7C, left).
A23187-induced PGE2 generation by cPLA2-COX-1
cotransfectants was about one tenth that by
cPLA2-COX-1-cPGES/p23 cotransfectants (Fig. 7C,
left), suggesting that the former occurs through the pathway
involving overexpressed cPLA2-COX-1 and endogenous
cPGES/p23. In contrast, PGE2 generation by
A23187-stimulated COX-2-expressing cells was increased only modestly
when cPLA2 and cPGES/p23 were coexpressed (Fig.
7C, left). Moreover, cPGES/p23 did not promote
delayed PGE2 biosynthesis induced by IL-1 even when
combined with cPLA2 and either of the two COX isozymes
(Fig. 7C, right). Collectively, these results
suggest that cPGES/p23 mediates COX-1-dependent immediate
PGE2 synthesis.
To ensure that the preferential coupling between COX-1 and cPGES/p23
was not a peculiarity of the 293 transfectants, we next examined the
functional coupling between the endogenous enzymes. When antisense
cDNA for cPGES/p23 was transiently transfected into rat
fibroblastic 3Y1 cells, in which COX-1-dependent immediate and COX-2-dependent delayed PGE2-biosynthetic
responses occur in response to A23187 and IL-1/TNF, respectively (23),
the expression of cPGES/p23, but not COX-1, protein was decreased by
half (Fig. 8A,
inset), with a concomitant reduction of PGES activity in
cell homogenates (Fig. 8A). Importantly, A23187-elicited immediate, but not IL-1/TNF-induced delayed, PGE2
generation was suppressed by half in cells transfected with the
cPGES/p23 antisense cDNA (Fig. 8B).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of cPGES/p23 antisense cDNA on
PGE2 generation in rat fibroblastic 3Y1 cells.
A, the PGES activity in the cytosol of 3Y1 cells 3 days
after transfection with cPGES/p23 antisense cDNA/pCR3.1 or empty
vector was assessed. The expression of cPGES/p23 and COX-1 proteins, as
assessed by immunoblotting, is shown in the inset.
B, the cells were stimulated for 30 min with 10 µM A23187 and for 12 h with 1 ng/ml mouse IL-1
plus 100 units/ml mouse TNF to assess the immediate and delayed
phases of PGE2 generation, respectively. PGE2
generation without stimuli was <1 ng/well in both phases (data not
shown).
|
|
 |
DISCUSSION |
In the present study, we have identified for the first time a
cytosolic form of PGES, which is fully functional in mammalian cells.
It is a GSH-requiring enzyme expressed in a wide variety of cells and
tissues, and is identical to p23, a putative chaperone molecule that
binds to the ATP-dependent conformation of hsp90 and
stabilizes preformed steroid hormone receptor/hsp90 heterocomplexes (18, 21, 24). p23 was initially suggested to be required for refolding
of the receptor to the steroid binding conformation (25). However,
subsequent studies demonstrated that p23 is not essential for the
folding change of the steroid hormone receptor (26) and that deletion
of the p23 gene in yeast does not ablate glucocorticoid receptor action
(27). It has recently been proposed that p23 might play some role(s) at
later steps in intracellular receptor-mediated signal transduction,
perhaps including receptor recycling and reversal of the response (28),
and the assembly of active telomerase complex (29). However, the
precise cellular functions of p23 have remained obscure.
Several lines of evidence suggest that p23 is a functional
GSH-dependent PGES. First, recombinant expression of p23 in
both bacteria and mammalian cells reproduced PGES activity
indistinguishable from that of the enzyme purified from rat brain in
terms of GSH requirement and CDNB sensitivity (Figs. 1-3). Unlike
typical cytosolic GSTs (20), the GST activity of recombinant p23 toward
several cytosolic GST substrates was negligible. These properties are similar to those of hematopoietic PGD2 synthase, another
GSH-requiring terminal prostanoid synthase belonging to the class
of GSTs (22). Second, as in the case of various cytosolic GSTs and
hematopoietic PGD2 synthase (20, 22), a tyrosine residue
near the N terminus of p23 is essential for enzyme activity (Fig. 4).
Third, moderate changes in expression of p23 mRNA and protein
paralleled that in PGES activity in rat brain cytosol following LPS
treatment (Figs. 1 and 5). Fourth, transfection of p23 into HEK293
cells dramatically increased the cells' capacity to produce
PGE2, particularly when combined with COX-1 (Fig. 7).
Finally, reduction of p23 expression by antisense treatment led to a
concomitant decrease in A23187-induced, COX-1-dependent
PGE2 generation in 3Y1 cells (Fig. 8). In contrast, p23
expression minimally affected COX-2-dependent
PGE2 generation (Figs. 7 and 8). Thus, cPGES/p23 is
preferentially linked with COX-1, a constitutive COX isozyme, promoting
the immediate PGE2 biosynthetic response, and
physiologically it may contribute to production of PGE2
required for the maintenance of tissue homeostasis.
Since cPGES/p23 was eluted at >50 kDa on gel filtration (Fig.
2C), it may form a homodimer, as do cytosolic GSTs (20), and this has been recently verified by others (30). Alternatively, it may
form a heterooligomer with other cellular components. The latter
possibility is in line with the notion that p23 assembles in the
hsp90-directed steroid hormone receptor (18, 21, 24-28) or telomerase
(29) complex. Since the other PGES peaks detected on gel filtration
(Fig. 2C) were CDNB-insensitive, it is likely that they
reflect the presence of multiple forms of PGES other than
CDNB-sensitive cPGES/p23 in cells.
That cPGES/p23 functions as a PGE2-biosynthetic enzyme and
as a putative chaperone of lipophilic steroid hormone receptors (18,
21, 24-28) implies its multifunctional role. This property is
reminiscent of that of lipocalin-type PGD2 synthase, which not only plays a role in production of PGD2 in the central
nervous system (31) but also binds to several lipophilic ligands, such as biliverdin, bilirubin, and thyroid hormones (32), and functions as a
retinoid transporter (33). PGF synthase is a member of the aldo-keto
reductase superfamily, the enzymes belonging to which exhibit reductase
activities toward various carbonyl compounds in addition to
PGH2 (34, 35). Whether cPGES/p23 displays enzymatic activity toward lipophilic substances other than PGH2
remains to be elucidated.
The Km value of the recombinant cPGES/p23 purified
from E. coli was calculated to be 14 µM, which
was comparable to the Km of other cytosolic terminal
PG synthases, including lung-type (10 µM) and liver-type
(25 µM) PGFSs (35) and hematopoietic PGD2
synthase (500 µM) (36), and the
Vmax value (190 nmol/min/mg) was also similar to
that of PGFSs (200-400 nmol/min/mg) (35), although the in
vitro assay conditions for each enzyme differ. It should be noted
that the activity of bacterially expressed cPGES/p23 appeared to be
approximately 1 order lower than that of the enzyme purified from rat
brain or the recombinant enzyme expressed in HEK293 cells. This may be
a reflection of the presence of certain interacting cofactor(s) in
samples prepared from mammalian sources. It is also possible that in
mammalian cells cPGES/p23 undergoes posttranslational modifications
such as phosphorylation, which may lead to enzymatic activation. In
support of this idea, cPGES/p23 has multiple putative phosphorylation
sites (18). Alternatively, a weaker activity of the bacterially
expressed enzyme may be caused by aberrant folding of the recombinant
protein in bacteria, by the linkage of the artificial tag to the C
terminus, or by the presence of substance(s), which interferes with
measurement of the activity, in samples.
The reason why cPGES/p23 prefers COX-1 to COX-2 is currently unknown.
cPGES/p23 is predominantly present in the cytosol (Fig. 6) distal from
the perinuclear COXs (37, 38), and its cytosolic location was not
altered by A23187 stimulation of cells (data not shown). Since COX-1,
rather than COX-2, spreads into the cytosol along the endoplasmic
reticular membrane (39, 40), albeit not in all cases (41), this subtle
difference in subcellular localization of the two COXs might account,
at least in part, for the COX-1 selectivity of cPGES/p23. Another
possibility is the presence of certain cofactor(s) that may assist the
functional coupling between COX-1 and cPGES/p23. Indeed,
5-lipoxygenase-activating protein acts as an essential cofactor that
links cPLA2 and 5-lipoxygenase by presenting AA released by
the former to the latter in the leukotriene-biosynthetic pathway (42).
As p23 reportedly assembles in a steroid hormone/hsp90 complex, which
translocates from the cytosol into the nucleus in a
ligand-dependent manner, steroid hormones may modulate the subcellular locations of cPGES/p23 and thereby alter its
PGE2-biosynthetic capacity in cells.
PGE2 is also produced in the delayed phase of the
inflammatory responses in vitro and in vivo,
during which COX-2, but not COX-1, plays a dominant role (1-3, 5, 11,
19, 23, 43). Considering that cPGES/p23 exerts its function only in
COX-1-dependent immediate PGE2 biosynthesis,
another PGES enzyme(s) that is selectively coupled with COX-2 in the
delayed response must exist in cells. In this context, MGST1-L1, a
member of the MAPEG superfamily (13, 14), is a strong candidate for the
terminal enzyme involved in this process. In the accompanying paper
(15), we provide evidence that MGST1-L1, a GSH-requiring, inducible
perinuclear PGES, promotes the COX-2-dependent
PGE2-biosynthetic pathway.
 |
FOOTNOTES |
*
This work was supported by grants-in-aid for scientific
research from the Ministry of Education, Science and Culture of Japan and special coordination funds for promoting science and technology from the Science and Technology Agency.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 81-3-3784-8196;
Fax: 81-3-3784-8245; E-mail: kudo@pharm.showa-u.ac.jp.
Published, JBC Papers in Press, August 1, 2000, DOI 10.1074/jbc.M003504200
 |
ABBREVIATIONS |
The abbreviations used are:
PG, prostaglandin;
cPGES, cytosolic prostaglandin E2 synthase;
PGES, prostaglandin E2 synthase;
COX, cyclooxygenase;
cPLA2, cytosolic phospholipase A2;
LPS, lipopolysaccharide;
GSH, glutathione;
GST, glutathione
S-transferase;
MGST1-L1, microsomal GST1-like 1;
AA, arachidonic acid;
CDNB, 1-chloro-2,4-dinitrobenzene;
IL, interleukin;
TNF, tumor necrosis factor;
FCS, fetal calf serum;
BSA, bovine serum
albumin;
PAGE, polyacrylamide gel electrophoresis;
CHO, Chinese hamster
ovary;
DMEM, Dulbecco's modified Eagle's medium;
PBS, phosphate-buffered saline;
PLA2, phospholipase
A2.
 |
REFERENCES |
| 1.
|
Murakami, M.,
Shimbara, S.,
Kambe, T.,
Kuwata, H.,
Winstead, M. V.,
Tischfield, J. A.,
and Kudo, I.
(1998)
J. Biol. Chem.
273,
14411-14423
|
| 2.
|
Murakami, M.,
Kambe, T.,
Shimbara, S.,
and Kudo, I.
(1999)
J. Biol. Chem.
274,
3103-3115
|
| 3.
|
Murakami, M.,
Kambe, T.,
Shimbara, S.,
Higashino, K.,
Hanasaki, K.,
Arita, H.,
Horiguchi, M.,
Arita, M.,
Arai, H.,
Inoue, K.,
and Kudo, I.
(1999)
J. Biol. Chem.
274,
31435-31444
|
| 4.
|
Kulmacz, R. J.,
and Wang, L.-H.
(1995)
J. Biol. Chem.
270,
24019-24023
|
| 5.
|
Smith, W. L.,
Garavito, R. M.,
and DeWitt, D. L.
(1996)
J. Biol. Chem.
271,
33157-33160
|
| 6.
|
Morita, I.,
Schindler, M.,
Regier, M. K.,
Otto, J. C.,
Hori, T.,
DeWitt, D. L.,
and Smith, W. L.
(1995)
J. Biol. Chem.
270,
10902-10908
|
| 7.
|
Tanaka, Y.,
Ward, S.,
and Smith, W. L.
(1987)
J. Biol. Chem.
262,
1374-1381
|
| 8.
|
Watanabe, K.,
Kurihara, K.,
and Hayaishi, O.
(1997)
Biochem. Biophys. Res. Commun.
235,
148-152
|
| 9.
|
Ogorochi, T.,
Ujihara, M.,
and Narumiya, S.
(1987)
J. Neurochem.
48,
900-909
|
| 10.
|
Watanabe, K.,
Kurihara, K.,
and Suzuki, T.
(1999)
Biochim. Biophys. Acta
1439,
406-414
|
| 11.
|
Naraba, H.,
Murakami, M.,
Matsumoto, H.,
Shimbara, S.,
Ueno, A.,
Kudo, I.,
and Oh-ishi, S.
(1998)
J. Immunol.
160,
2974-2982
|
| 12.
|
Fournier, T.,
Fadok, V.,
and Henson, P. M.
(1997)
J. Biol. Chem.
272,
31065-31072
|
| 13.
|
Jakobsson, P.-J.,
Thoren, S.,
Morgenstern, R.,
and Samuelsson, B.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
7220-7225
|
| 14.
|
Jakobsson, P.-J.,
Morgenstern, R.,
Mancini, J.,
Ford-Hunchinton, A.,
and Persson, B.
(1999)
Protein Sci.
8,
689-692
|
| 15.
|
Murakami, M.,
Naraba, H.,
Tanioka, T.,
Semmyo, N.,
Nakatani, Y.,
Kojima, F.,
Ikeda, T.,
Fueki, M.,
Ueno, A.,
Oh-ishi, S.,
and Kudo, I.
(2000)
J. Biol. Chem.
275,
32783-32792
|
| 16.
|
Murakami, M.,
Matsumoto, R.,
Austen, K. F.,
and Arm, J. P.
(1994)
J. Biol. Chem.
269,
22269-22275
|
| 17.
|
Nakatani, Y.,
Tanioka, Y.,
Sunaga, S.,
Murakami, M.,
and Kudo, I.
(2000)
J. Biol. Chem.
275,
1161-1168
|
| 18.
|
Johnson, J. L.,
Beito, T. G.,
Krco, C. J.,
and Toft, D. O.
(1994)
Mol. Cell. Biol.
14,
1956-1963
|
| 19.
|
Murakami, M.,
Nakatani, Y.,
and Kudo, I.
(1996)
J. Biol. Chem.
271,
30041-30051
|
| 20.
|
Salinas, A. E.,
and Wong, M. G.
(1999)
Curr. Med. Chem.
6,
279-309
|
| 21.
|
Hutchinson, K. A.,
Stancato, L. F.,
Qwens-Grillo, J. K.,
Johnson, J. L.,
Krishna, P.,
Toft, D. O.,
and Pratt, W. B.
(1995)
J. Biol. Chem.
270,
18841-18847
|
| 22.
|
Kanaoka, Y.,
Ago, H.,
Inagaki, E.,
Nanayama, T.,
Miyano, M.,
Kikuno, R.,
Fujii, Y.,
Eguchi, N.,
Toh, H.,
Urade, Y.,
and Hayaishi, O.
(1997)
Cell
90,
1085-1095
|
| 23.
|
Kuwata, H.,
Nakatani, Y.,
Murakami, M.,
and Kudo, I.
(1998)
J. Biol. Chem.
273,
1733-1740
|
| 24.
|
Sullivan, W.,
Stensgard, B.,
Caucutt, G.,
Bartha, B.,
McMahon, N.,
Alnemri, E. S.,
Litwack, G,
and Toft, D.
(1997)
J. Biol. Chem.
272,
8007-8012
|
| 25.
|
Dittmar, K. D.,
Demady, D. R.,
Stancato, L. F.,
Krishna, P.,
and Pratt, W. B.
(1997)
J. Biol. Chem.
272,
21213-21220
|
| 26.
|
Morishima, Y.,
Kanelakis, K. C.,
Silverstein, A. M.,
Dittmar, K. D.,
Estrada, L.,
and Pratt, W. B.
(2000)
J. Biol. Chem.
275,
6894-6900
|
| 27.
|
Bohenm, S. P.
(1998)
Mol. Cell. Biol.
18,
3330-3339
|
| 28.
|
Freeman, B. C.,
Felts, S. J.,
Toft, D. O.,
and Yamamoto, K. R.
(2000)
Genes Dev.
14,
422-434
|
| 29.
|
Holt, S. E.,
Aisner, D. L.,
Baur, J.,
Tesmer, V. M.,
Dy, M.,
Ouellette, M.,
Trager, J. B.,
Morin, G. B.,
Toft, D. O.,
Shay, J. W.,
Wright, W. E.,
and White, M. A.
(1999)
Genes Dev.
13,
817-826
|
| 30.
|
Weaver, A. J.,
Sullivan, W. P.,
Felts, S. J.,
Owen, B. A.,
and Toft, D. O.
(2000)
J. Biol. Chem.
275,
23045-23052
|
| 31.
|
Nagata, A.,
Suzuki, Y.,
Igarashi, M.,
Eguchi, N.,
Toh, H.,
Urade, Y.,
and Hayaishi, O.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4020-4024
|
| 32.
|
Beuckmann, C. T.,
Aoyagi, M.,
Okazaki, I.,
Hiroike, T.,
Toh, H.,
Hayaishi, O.,
and Urade, Y.
(1999)
Biochemistry
38,
8006-8013
|
| 33.
|
Tanaka, T.,
Urade, Y.,
Kimura, H.,
Eguchi, N.,
Nishikawa, A.,
and Hayaishi, O.
(1997)
J. Biol. Chem.
272,
15789-15795
|
| 34.
|
Watanabe, K.,
Yoshida, R.,
Shimizu, T.,
and Hayaishi, O.
(1985)
J. Biol. Chem.
260,
7035-7041
|
| 35.
|
Suzuki, T.,
Fujii, Y.,
Miyano, M.,
Chen, L. Y.,
Takahashi, T.,
and Watanabe, K.
(1999)
J. Biol. Chem.
274,
241-248
|
| 36.
| Pinzar, E., Miyako, M., Kanaoka, Y., Urade, Y., and Hayaishi, O. (2000)
J. Biol. Chem. 275, in press
|
| 37.
|
Spencer, A. G.,
Woods, J. W.,
Arakawa, T.,
Singer, I. I.,
and Smith, W. L.
(1998)
J. Biol. Chem.
273,
9886-9893
|
| 38.
|
Murakami, M.,
Kambe, T.,
Shimbara, S.,
Yamamoto, S.,
Kuwata, H.,
and Kudo, I.
(1999)
J. Biol. Chem.
274,
29927-29936
|
| 39.
|
Morita, I.,
Schindler, M.,
Reiger, M. K.,
Otto, J. C.,
Hori, T.,
DeWitt, D. L.,
and Smith, W. L.
(1995)
J. Biol. Chem.
270,
10902-10908
|
| 40.
|
Liou, J.-Y.,
Shyue, S.-K.,
Tsai, M.-J.,
Chung, C.-L.,
Chu, K.-Y.,
and Wu, K. K.
(2000)
J. Biol. Chem.
275,
15314-15320
|
| 41.
|
Spencer, A. G.,
Woods, J. W.,
Arakawa, T.,
Singler, I. I.,
and Smith, W. L.
(1998)
J. Biol. Chem.
273,
9886-9893
|
| 42.
|
Dixon, R. A.,
Diehl, R. E.,
Opas, E.,
Rands, E.,
Vickers, P. J.,
Evans, J. F.,
Gillard, J. W.,
and Miller, D. K.
(1990)
Nature
343,
282-284
|
| 43.
|
Harada, Y.,
Hatanaka, K.,
Kawamura, M.,
Saito, M.,
Ogino, M.,
Majima, M.,
Ohno, T.,
Ogino, K.,
Yamamoto, K.,
Taketani, Y.,
Yamamoto, S.,
and Katori, M.
(1996)
Prostaglandins
51,
19-33
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Hammarberg, M. Hamberg, A. Wetterholm, H. Hansson, B. Samuelsson, and J. Z. Haeggstrom
Mutation of a Critical Arginine in Microsomal Prostaglandin E Synthase-1 Shifts the Isomerase Activity to a Reductase Activity That Converts Prostaglandin H2 into Prostaglandin F2{alpha}
J. Biol. Chem.,
January 2, 2009;
284(1):
301 - 305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Jadhav, A. Jabre, M.-F. Chen, and T. J.-F. Lee
Presynaptic Prostaglandin E2 EP1-Receptor Facilitation of Cerebral Nitrergic Neurogenic Vasodilation
Stroke,
January 1, 2009;
40(1):
261 - 269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. N. Somayaji, S. Ritchie, M. Sahraei, I. Marriott, and M. C. Hudson
Staphylococcus aureus Induces Expression of Receptor Activator of NF-{kappa}B Ligand and Prostaglandin E2 in Infected Murine Osteoblasts
Infect. Immun.,
November 1, 2008;
76(11):
5120 - 5126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M Korotkova, S B. Helmers, I Loell, H Alexanderson, C Grundtman, C Dorph, I E Lundberg, and P-J Jakobsson
Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis
Ann Rheum Dis,
November 1, 2008;
67(11):
1596 - 1602.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Monfort, J-P Pelletier, N Garcia-Giralt, and J Martel-Pelletier
Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues
Ann Rheum Dis,
June 1, 2008;
67(6):
735 | |